DALLAS, Nov. 6, 2025 /PRNewswire/ -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) today announced the addition of Starjemza®, a new biosimilar medication, to its growing portfolio of affordable ...
The rise of more transparent, “Cost Plus” pharmacy models is stirring debate within the pharmaceutical space as smaller players put pressure on the large PBMs. In January 2022, entrepreneur Mark Cuban ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results